242 related articles for article (PubMed ID: 35948482)
1. Intravesical Therapy Compared to Radical Cystectomy Among Patients With Non-Muscle Invasive Bladder Cancer Requiring Additional Treatment After Induction BCG.
Anderson CB; Chen L; Chang SS; McKiernan JM; Wright J
Clin Genitourin Cancer; 2022 Dec; 20(6):595-603. PubMed ID: 35948482
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
[TBL] [Abstract][Full Text] [Related]
3. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
4. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy.
Contieri R; Hensley PJ; Tan WS; Grajales V; Bree K; Nogueras-Gonzalez GM; Lee BH; Navai N; Dinney CP; Kamat AM
Eur Urol Oncol; 2023 Dec; 6(6):590-596. PubMed ID: 37558542
[TBL] [Abstract][Full Text] [Related]
5. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy.
Lambert EH; Pierorazio PM; Olsson CA; Benson MC; McKiernan JM; Poon S
BJU Int; 2007 Jul; 100(1):33-6. PubMed ID: 17552951
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
[TBL] [Abstract][Full Text] [Related]
7. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
[TBL] [Abstract][Full Text] [Related]
8. The association of salvage intravesical therapy following BCG with pathologic outcomes and survival after radical cystectomy for patients with high-grade non-muscle invasive bladder cancer: A multi-institution analysis.
Packiam VT; Labbate CV; Boorjian SA; Tarrell R; Cheville JC; Avulova S; Sharma V; Tsivian M; Adamic B; Mahmoud M; Werntz RP; Smith ND; Karnes RJ; Tollefson MK; Steinberg GD; Frank I
Urol Oncol; 2021 Jul; 39(7):436.e1-436.e8. PubMed ID: 33485764
[TBL] [Abstract][Full Text] [Related]
9. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
[TBL] [Abstract][Full Text] [Related]
10. Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.
Murakami Y; Matsumoto K; Miyake M; Amano N; Shimura S; Nishimura N; Iida K; Matsushita Y; Abe T; Yamada T; Uemura M; Matsui Y; Taoka R; Kojima T; Kobayashi T; Nishiyama N; Kitamura H; Nishiyama H; Fujimoto K; Iwamura M
Int J Urol; 2022 Oct; 29(10):1195-1203. PubMed ID: 35858755
[TBL] [Abstract][Full Text] [Related]
11. Underutilization of intravesical chemotherapy and immunotherapy for high grade non-muscle invasive bladder cancer in California between 2006-2018: Effect of race, age and socioeconomic status on treatment disparities.
Noel OD; Stewart E; Cress R; Dall'Era MA; Shrestha A
Urol Oncol; 2023 Oct; 41(10):431.e7-431.e14. PubMed ID: 37295979
[TBL] [Abstract][Full Text] [Related]
12. Impact of intravesical Bacillus Calmette-Guérin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer.
James C; Gomez K; Desai S; Patel HD; Rac G; Doshi CP; Dornbier R; Bajic P; Halverson T; Gupta GN; Quek ML; Gorbonos A; Flanigan R; Wolfe AJ
Front Cell Infect Microbiol; 2023; 13():1125809. PubMed ID: 37091677
[TBL] [Abstract][Full Text] [Related]
13. Incidence and management of prostatic urethra recurrence in a cohort of 21 patients who received BCG induction for non-muscle invasive bladder cancer.
Ingram JW; Chung R; Laplaca C; McKiernan JM; Lenis AT; Anderson CB
Urol Oncol; 2024 Sep; 42(9):290.e11-290.e16. PubMed ID: 38688797
[TBL] [Abstract][Full Text] [Related]
14. Bacillus Calmette-Guerin (BCG) therapy is safe and effective in non-muscle invasive bladder cancer (NMIBC) patients with immunomodulating conditions.
Durant AM; Choudry MM; Madura G; Mi L; Faraj KS; Tyson MD
Urol Oncol; 2024 Jan; 42(1):21.e21-21.e28. PubMed ID: 37852817
[TBL] [Abstract][Full Text] [Related]
15. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
16. Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non-muscle-invasive bladder cancer after BCG failure.
Hurle R; Contieri R; Casale P; Morenghi E; Saita A; Buffi N; Lughezzani G; Colombo P; Frego N; Fasulo V; Paciotti M; Guazzoni G; Lazzeri M
Urol Oncol; 2021 Mar; 39(3):195.e7-195.e13. PubMed ID: 33268275
[TBL] [Abstract][Full Text] [Related]
17. Oncologic outcomes of intravesical therapy in the management of nonmuscle invasive bladder cancer with variant histology.
Lone Z; Benidir T; Wood A; Campbell RA; Alaghehbandan R; Li J; Haber GP; Eltemamy M; Haywood SC; Weight CJ; Lee BH; Almassi N
Urol Oncol; 2024 Mar; 42(3):71.e1-71.e7. PubMed ID: 38135626
[TBL] [Abstract][Full Text] [Related]
18. Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer.
Singla N; Haddad AQ; Passoni NM; Meissner M; Lotan Y
World J Urol; 2017 Jan; 35(1):105-111. PubMed ID: 27194044
[TBL] [Abstract][Full Text] [Related]
19. Prognostication in Japanese patients with bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer undergoing early radical cystectomy.
Nishimura N; Miyake M; Iida K; Miyamoto T; Tomida R; Numakura K; Inokuchi J; Yoneyama T; Matsumura Y; Yajima S; Masuda H; Terada N; Taoka R; Kobayashi T; Kojima T; Matsui Y; Nishiyama N; Kitamura H; Nishiyama H; Fujimoto K
Int J Urol; 2022 Mar; 29(3):242-249. PubMed ID: 34902876
[TBL] [Abstract][Full Text] [Related]
20. Failure of Bacillus Calmette-Guérin therapy in non-muscle-invasive bladder cancer: Definition and treatment options.
Gual Frau J; Palou J; Rodríguez O; Parada R; Breda A; Villavicencio H
Arch Esp Urol; 2016 Sep; 69(7):423-33. PubMed ID: 27617552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
